Has come back (relapsed) within a year of treatment or does not go away (refractory) after your first treatment Has relapsed or is refractory and you cannot receive a hematopoietic stem cell ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

Our immune systems have the thankless jobs of guarding us from bacterial and viral invaders and preventing cancer development. Most of the time, we do not notice this hard work because the invaders ...